Europeiska unionen - svenska - EMA (European Medicines Agency)

virbac s.a. - osateronacetat - urologiska - hundar - behandling av godartad prostatahypertrofi (bph) hos hanhundar.

Europeiska unionen - svenska - EMA (European Medicines Agency)

janssen-cilag international n.v. - abirateronacetat - prostatiska neoplasmer - endokrin terapi - zytiga är markerad med prednison eller prednisolon för:behandling av metastaserande kastrering resistent prostatacancer hos vuxna män som är asymptomatiska eller lindrigt symptomatiska efter bortfall av androgen fattigdom terapi i vilken kemoterapi är ännu inte kliniskt indicatedthe behandling av metastaserande kastrering resistent prostatacancer hos vuxna män vars sjukdom har kommit på eller efter ett docetaxel-baserad kemoterapi regim.

Europeiska unionen - svenska - EMA (European Medicines Agency)

recordati rare diseases - ibuprofen - ductus arteriosus, patent - hjärtbehandling - behandling av ett hemodynamiskt signifikant patent ductus arteriosus hos prematura nyfödda spädbarn under 34 veckors gestationsålder.

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - abirateronacetat - prostatiska neoplasmer - endokrin terapi - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Europeiska unionen - svenska - EMA (European Medicines Agency)

krka, d.d., novo mesto - abirateronacetat - prostatiska neoplasmer - endokrin terapi - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - relugolix - prostatiska neoplasmer - endokrin terapi - orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - leuprorelin mesilate - prostatiska neoplasmer - endokrin terapi - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

zoetis belgium sa - live recombinant e2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus e2 gene (cp7_e2alf) - live viral vaccines, immunologicals for suidae - grisar - för aktiv immunisering av grisar från 7 veckors ålder och framåt för att förebygga dödlighet och minska infektion och sjukdom som orsakas av klassisk svinpestvirus (csfv). onset of immunity: 14 days after vaccinationduration of immunity: at least 6 months after vaccinationfor active immunisation of breeding females to reduce transplacental infection caused by csfv. onset of immunity: 21 days after vaccinationduration of immunity has not been demonstrated.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sandoz a/s - leuprorelinacetat - implantat - 3,6 mg - leuprorelinacetat 3,78 mg aktiv substans - leuprorelin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sandoz a/s - leuprorelinacetat - implantat - 5 mg - leuprorelinacetat 5,25 mg aktiv substans - leuprorelin